MODEL VERDICT
Milestone Pharmaceuticals Inc. (MIST) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.00 | 2.48 | 1.37 | 11.17 | 3.64 |
| P/B Ratio | 4.00 | 2.48 | 1.37 | 11.17 | 3.64 |
| P/S Ratio | 41.21 | 33.62 | 18.27 | 71.74 | 27.53 |
Insufficient data to determine relative valuation for MIST.
Fair value could not be computed for MIST due to insufficient comparable data.
MIST's current P/E of -2.7x compares to the industry median of 23.5x (45 peers in the group). This represents a -111.6% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
7 analysts cover MIST with a consensus rating of Buy. The consensus price target is $8.00 (range: $8.00 — $8.00), implying +339.6% upside from the current price. Grade breakdown: Strong Buy (0), Buy (6), Hold (1), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for MIST.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.